Category Archives: Cancer Research

Mikhail Blagosklonny’s Passion Is a Light at the End of the Tunnel

Mikhail Blagosklonny is a scientist who has an interest in cancer and aging. The research that he does mostly range in translating the current science into new anticancer strategies; he wants to find the answer to protecting normal cells by studying drug resistance and cancer cell cycling. He also does research on molecular, cellular biology and clinical investigations; including mitosis, apoptosis, tumor suppression and oncogenes. Rapamycin is a popular cancer drug that Dr. Blagosklonny revealed can be used as an anti-aging; following his research on aging he concluded that the drug could prolong life.

Mikhail Blagosklonny attained both his Doctor of Medicine in internal medicine and Ph.D. in Experimental Medicine and Cardiology at the First Pavlov State Medical University of St. Peterburg. Currently, he is an oncology professor at the Roswell Park Cancer Institute since 2009; he worked previously at the New York Medical College as an associate professor of medicine in 2002, then, he was a senior scientist at Ordway Research Institute.

Mikhail has a broad range of skills and expertise ranging from transitional medicine, chemoprevention, cancer biomarkers, protein kinases and many others, with all these it is difficult to deny that he is among the top scientists. Students at Roswell Park Cancer Institute have the privilege to learn from the best.

Apart from teaching and research Dr. Mikhail is the chief editor of Aging, Cell Cycle and Oncotarget, associate editor of Cancer Biology and Therapy and is also on the board of editors of Cell Death and Differentiation. In the peer review journals, Blagosklonny has published over two hundred and seventy papers and over twenty-five thousand citations. His publications are very informative and come in a lot of people have interest in them.

Dr. Mikhail Blagosklonny is considered to be very passionate about his research and it is the reason he has been given high position in cancer and aging-related reviews and institutions. With his kind of determination with time he will make significant steps that will assist cancer patients; maybe, something that world will be able to use so that cancer can be fought ones and for all. View his profile on LinkedIn.

Investors in Seattle Genetics Can Celebrate

Seattle Genetics is a biotechnology company that constantly looks for new ways to treat cancer. It was founded by Clay Siegall in 1998. He serves as the CEO of the company and is on its Board of Directors. The company has a wide portfolio of preclinical and clinical products that treat autoimmune conditions and cancer. It does this in part through antibody technology. It has done pioneering work in the field of antibody-drug conjugates.

Dr. Siegall has managed to raise $330 million in funds for research and development of new treatment methods. The company went public in 2001 and has been thriving since that time. It has chosen key strategic partners to fuel its rise up the financial ladder. A deal was made with Genentech which is worth $860 million.

Clay Siegall worked at the National Cancer Institute and the National Institutes of Health. He still serves on the Board of Directors for Alder Biopharmaceuticals. He is on the board for the Fred Hutchinson Cancer Research Business Alliance. He has a doctorate degree from the University of Maryland where he specialized in Genetics.

A new treatment is being tested which has the potential to help millions of women each year who suffer from breast cancer. More than 1.6 million people are diagnosed with this disease every single year. The worst type of cancer you can acquire is triple negative metastatic which means that it can’t be detected from any of the early biomarkers. These biomarkers are how the typical therapeutic drugs improve the condition of patients. Seattle Genetics’s new drug provides hope to triple negative breast cancer patients. In the latest trial, there was a 37% response rate. This is a higher response rate than any other drug on the market for these patients. More testing needs to be done, but if they prove successful it is thought that these new therapies will save lives and be lucrative for Seattle Genetics’s stock price. Its investors have a true reason to celebrate. Anti-body technology that delivers payloads into cancer cells is proving to be remarkably effective means of fighting cancer. Seattle Genetics is one of the industry pioneers when it comes to this method of treatment.